Aaron Rosenberg - 03 Aug 2026 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Reporting relationship: Chief Financial Officer
Issuer ticker: ONC
Reported as of: 03 Aug 2026
Net transaction value: -$361,811
SEC form: 4
Accepted by SEC: 05 Aug 2026, 17:15:58 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Chan Henry Lee, as Attorney-in-Fact

Key filing fact

Aaron Rosenberg filed Form 4 for BeOne Medicines Ltd. (ONC) on 05 Aug 2026.

Key facts

This page summarizes Aaron Rosenberg's Form 4 filing for BeOne Medicines Ltd. (ONC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Aug 2026, 17:15.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: -$361,811.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002031182 Primary reporting owner

Rosenberg Aaron

Relationship: Chief Financial Officer
Address: C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND
Signature: /s/ Chan Henry Lee, as Attorney-in-Fact
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONC transaction

American Depositary Shares

Sale

Transaction value: $361,811
Shares: -1,157
Change %: -100%
Price: $312.72
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 382,850
Date: 03 Aug 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each American Depositary Share represents 13 Ordinary Shares.

Footnote F2

The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of July 31, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.